Concerning response to treatment and overall prognosis, all patients experienced a complete response to induction therapy with rapid decrease in leukocytosis and resolution of extramedullary involvement under corticosteroid therapy. MRD, when applicable, was found negative at the end of induction, underlying high sensitivity to chemotherapy. This high chemosensitivity contrasted with the high incidence of relapse (occurring in three of our cases) and poor overall prognosis. This finding underlines the importance of quick identification of this rearrangement to propose treatment adaptation to high-risk groups, including allogeneic marrow transplantation consideration before facing potentially chemoresistant relapse.
Chronic myeloproliferative diseases (CMPDs) are clonal disorders of haematopoietic stem cells and are classified according to their clinical and phenotypical features and genetic aberrations. 1 CMPDs are usually divided according to the presence of a Philadelphia chromosome/BCR-ABL fusion (Ph þ ) as chronic myeloid leukaemia (CML) and the Philadelphia chromosome negative (Ph À ) CMPD (polycythaemia vera (PV), essential thrombocythaemia (ET), primary myelofibrosis (PMF)). More than 95% of PV and B60% of ET and PMF are positive for the 1849G4T/V617F point mutation of the Janus kinase 2 (JAK2 V617F ), which is highly specific for Ph À -CMPD. 1 Small subfractions of ET and PMF (B5%) show another gain of function mutation that affects the thrombopoietin receptor (1544G4T/A/W515L/K in the myeloproliferative leukaemia virus oncogene, (MPL W515L/K )). 1 A subgroup of Ph þ -CML mimics ET or PMF by presenting with marked thrombocytosis or myelofibrosis (MF), but only single cases with concomitant Ph þ -CML and Ph À -CMPD were reported so far. [2] [3] [4] [5] Recently, our group Inami et al., Krämer et al., and Bornhäuser et al. [2] [3] [4] [5] simultaneously reported on four well-documented cases with concurrent JAK2 V617F and BCR-ABL translocation ( Table 1) . The tyrosine kinase abnormalities appeared to affect independent subclones because imatinib mesylate (IM) treatment induced Ph þ -CML remission whereas the JAK2 V617F clone either persisted or became clinically manifest as PMF [2] [3] [4] or PV. 5 In our previously reported case, a minor JAK2 V617F clone expanded after major response of Ph þ -CML to IM. 2 In search for parallel cases, we discovered a total of four CMPD cases of concurrent BCR-ABL and JAK2 V617F mutation in the Hannover bone marrow registry (Table 1 ). In one of these Ph þ -CML cases similar to the previously published cases, 2-5 the concurrent JAK2 V617F clone became clinically manifest subsequently to IM-induced suppression of the BCR-ABL clone. In another case, a shift of phenotype from CML to JAK2 V617F -positive PMF occurred during treatment with IM. One longlasting JAK2 V617F -positive PV case acquired the BCR-ABL aberration and in one Ph þ -CML case, the JAK2 V617F clone was clinically silent. Remarkably, the majority of patients with concurrent BCR-ABL and JAK2 V617F reported up to now, including this series, were male (Table 1) .
Previously established methods for molecular analysis of formalin-fixed and paraffin-embedded bone marrow (BM) biopsies were used for the detection of BCR-ABL transcripts and pyrosequencer assay was used for the quantification of JAK2 V617F and MPL W515L/K mutant allele frequencies.
2,7 Abbreviations: all data refer to status before treatment (b); AG, anagrelide; +, positive; À, negative; BM, bone marrow; PB, peripheral blood; m, elevated value;~female; HB, haemoglobin; IFN, interferon-a, ; IM, imatinib mesylate; JAK2 V617F %, mutant allele frequency; LDH, lactate dehydrogenase; #, male; ND, not determined; n.r., normal range of haematological parameters; (a) Philadelphia chromosome in cytogenetic analysis; PLT, platelet count; HU, hydroxyurea; WBC, white blood cell count.
A 32-year-old male (#1) presented with thrombocytosis (platelet count: 1 year before diagnosis 618 Â 10 9 l À1 , and at diagnosis 1120 Â 10 9 l À1 ). BM examination of this subject in an external clinic revealed CMPD, most likely an ET, but three years later the diagnosis was reversed and corrected into Ph þ -CML with thrombocytosis. DNA analysis of BM biopsy, which was taken in another hospital at that time revealed no detectable JAK2
V617F
. According to the initial ET diagnosis, the therapy was commenced with anagrelide and was switched to hydroxyurea after splenomegaly and leukocytosis (white blood cell count (WBC) 21 Â 10 9 l À1 ) had occurred. Due to an allergic reaction with dermal irritation and increase of thrombocytosis (platelet count 1000 Â 10 9 l À1 ), 2 months later anagrelide was reintroduced and replaced hydroxyurea. No positive effect on clinical parameters could be achieved (fever, weight loss, increased splenomegaly, WBC 35 Â 10 9 l À1 , platelet count 907 Â 10 9 l À1 and lactate dehydrogenase 599 U l
À1
). Furthermore, 40 months after initial presentation peripheral blood analysis revealed 12% blasts and BCR-ABL transcripts (b3a2) were detectable in BM and peripheral blood. Subsequently, the regime was changed to IM treatment and 4 months later BCR-ABL was no longer detectable. BM histology at that time revealed Ph À -CMPD phenotype with enlarged and clustered megakaryocytes whereas the retrospectively examined biopsy taken in another hospital at the onset of disease showed the characteristic small megakaryocytes of CML. The shift of phenotype was paralleled by a JAK2 V617F mutation affecting 21% of alleles. The sensitivity of our technique is 1% of mutated alleles, consequently, we cannot exclude that at initial presentation (in the first BM biopsy), the JAK2 V617F clone was too negligible for detection. IM was continued and after 6 and 9 months, JAK2 V617F decreased to 5 and 6% mutant alleles respectively. Splenomegaly was no longer present and haematological parameters were stabilized but BM histology still revealed some atypical megakaryocytes.
Since PMF phenotype was present in previously published cases, [2] [3] [4] we selected 18 Ph þ -CML cases that developed MF during the course of disease from 1999 to 2007. Among this cohort, there was a 58-year-old woman (#2) who suffered from CML for 1 year. Cytogenetic analysis showed Ph þ . Treatment was started with hydroxyurea and was continued with interferon-a. At the time of BM biopsy mild leukocytosis, elevated lactate dehydrogenase and splenomegaly were found. Molecular analysis yielded 23% JAK2 V617F alleles but due to poor RNA quality the BCR-ABL status could not be evaluated. Histological examination revealed reduced granulopoiesis and erythropoiesis and also severe MF with atypical megakaryocytes characteristic for PMF.
Similar to the patient presented by Haq, 8 we found a case of Ph þ -CML developing in a patient with long-lasting PV. This male patient (#3) had a 15-year history of PV and the BM biopsy that was taken at the time of initial diagnosis yielded 62% JAK2 V617F mutant allele burden but no detectable BCR-ABL transcripts. The patient was 63-years old when peripheral blood parameters revealed increasing leukocytosis and BM morphology displayed the development of mild MF and a shift to CML phenotype. Molecular analysis done on the corresponding BM biopsy showed 75% JAK2 V617F mutant alleles and a simultaneous BCR-ABL transcript (b3a2). Subsequently, IM treatment induced molecular remission of BCR-ABL after 5 months but not that of the JAK2 V617F clone (51% mutant allele frequency). The regime was changed to IM with IFN-a. After additional 6 months, severe MF and splenomegaly developed while the JAK2 V617F clone persisted (53% mutant allele frequency). Later, 34 months after the first detection of BCR-ABL/JAK2 V617F double aberration, BM histology and immunohistochemistry revealed transformation into a CD34 þ /myeloperoxidase þ acute myeloid leukaemia. The JAK2 V617F mutant alleles had increased to 90% but BCR-ABL transcript was no longer detectable. Consequently, blasts most likely were originated from the JAK2 V617F clone. The patient succumbed to the blast crisis shortly afterwards. Aspiration with pneumonia and gastrointestinal bleeding were identified as the cause of death by post-mortem examination. Similar to this case the previously reported post-PV Ph þ -CML case 8 also showed therapy-refractory blast crisis in the course of the disease. In contrast, Inami et al. 5 presented a case with initial CML where the patient later developed PV and remained stable for several years and no acute myeloid leukaemia transformation has been observed as yet.
In a subfraction of double-mutated CMPD cases, the coexisting and latent JAK2 V617F mutated Ph À -CMPD became evident only after successful cytoreductive treatment. Clinically, the emerging JAK2 V617F -positive disease was considered as relapse or drug resistance of CML although BCR-ABL transcripts could not be detected. The BM histology revealed a shift of phenotype to Ph À -CMPD with fibrosis 2-4 and JAK2 V617F was Figure 1 Histomorphology of BCR-ABL/JAK2
V617F -CMPD at presentation. Bone marrow histology of patient 4 revealed a prominent and left shifted proliferation of granulopoiesis with paratrabecular rims of promyelocytes, typical for CML (a, Giemsa stain, original magnification Â 200). The megakaryocytes were increased in number and size with bizarre nuclei that usually are found in Philadelphiachromosome negative CMPD (b, Giemsa stain, original magnification Â 400 and inset in a). Images were produced with a microscope (BX51), digital camera (DP50) and software (DP 3.1) all produced by Olympus (Germany). already detectable at presentation with different allele frequencies between B2 and B38%. [2] [3] [4] [5] In these cases, JAK2
V617F detection was performed retrospectively after successful IMinduced suppression of the BCR-ABL clone and after a shift of phenotype had occurred during treatment. [2] [3] [4] [5] Occasionally BM biopsies are able to identify a Ph þ -CML/Ph À -CMPD case already at presentation. A 45-year-old male (#4) got a BM biopsy in order to clarify leukocytosis (WBC 57.54 Â 10 9 l À1 ).The BM analysis revealed a CML with BCR-ABL transcript (b3a2) with a massive granulocytosis but also with unusually large and clustering megakaryocytes that are not characteristic for CML but for Ph À -CMPD (Figure 1 ). Consequently, a JAK2 V617F analysis was initiated although no thrombocytosis was evident (platelet count 266 Â 10 9 l À1 ). A concurrent JAK2 V617F mutation (43% allele frequency) could be demonstrated. The therapy was started with IM and 8 months later the molecular remission of the Ph þ -CML was achieved while JAK2 V617F was still detectable (data not shown).
The frequency of BCR-ABL transcript and concurrent JAK2 V617F might be low in CMPD but probably more frequent than indicated by the first published series of JAK2 V617F mutation in CMPD. In this study we analysed 33 randomly selected Ph þ -CML cases and previously we have also analysed 87 randomly selected cases.
2 but none of these 120 Ph þ -CML cases, including 24 cases with thrombocytosis 4600 Â 10 9 l À1 , revealed JAK2
V617F
. Further studies on larger cohorts are needed to clarify the coexistence of JAK2 V617F and BCR-ABL in CMPD. Of note, in three of the published cases [2] [3] [4] [5] and in two cases of this series, BM histomorphology revealed a shift of phenotype from CML to Ph À -CMPD during treatment and highlighted the importance of routine BM biopsy in CMPD as a sensitive followup tool for the detection of Ph þ -CML/Ph À -CMPD coexistence. In conclusion, we suggest additional JAK2 V617F testing in Ph þ -CML cases when (i) abnormal blood values indicate IM therapy failure but the Philadelphia chromosome abnormality does not re-emerge (ii) the BM histology reveals MF and/or enlarged and clustered megakaryocytes either at presentation or during the course of disease. Systemic sclerosis (SSc) is an autoimmune connective tissue disorder characterized by activation of the immune system, by vasculopathy due to a dysfunction of endothelial cells and by the excessive deposition of collagen in the skin and various internal organs. Prognosis is poor in individuals presenting with diffuse cutaneous, lung or renal involvement. As of now, there is no effective treatment for the disease and SSc is generally regarded as refractory to conventional immunosuppression.
Mesenchymal stem cells (MSCs) possess immunosuppressive capacities in an allogeneic host. This has been successfully utilized in the treatment of steroid refractory acute graft versus host (aGVH), 1 a condition sharing similarities with SSc. To date,
